Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 20Active not recruiting 18Recruiting 8Terminated 4Withdrawn 3Unknown 3Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 8Dermatologic 7Gastrointestinal 6Thoracic 5Head & Neck 5Sarcoma 2Lymphoid 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hodgkin Disease 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

Doxorubicin 5Cyclophosphamide 4Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2anlotinib 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1relmacabtagene autoleucel 1regorafenib 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1irinotecan sucrosofate 1fludarabine 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Nivolumab × Sarcoma × Clear all
NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
18 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡